This compound favoring muscarinicM2R and M4R may serve as a new lead structurefor further structural modifications to develop a novel class of selectiveM2R antagonists useful in the treatment of cognition deficitdiseases such as Alzheimer’s disease, schizophrenia, or CNSlearning disorders, such as autism or attention deficit disorder. The gene discussed is CHRM4; the disease is schizophrenia.